According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
Separately, BMO Capital Markets started coverage on shares of Neos Therapeutics in a research note on Tuesday, June 28th. They set an outperform rating and a $15.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and a consensus price target of $20.94.
Shares of Neos Therapeutics (NASDAQ:NEOS) opened at 6.37 on Wednesday. The stock’s 50 day moving average is $7.04 and its 200 day moving average is $8.57. Neos Therapeutics has a 12 month low of $6.31 and a 12 month high of $16.70. The company’s market capitalization is $102.37 million.
Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.16) by $0.49. The firm had revenue of $1.49 million for the quarter, compared to the consensus estimate of $1.48 million. Neos Therapeutics had a negative return on equity of 80.10% and a negative net margin of 968.81%. On average, equities analysts predict that Neos Therapeutics will post ($5.39) EPS for the current fiscal year.
In related news, CFO Richard I. Eisenstadt bought 3,710 shares of the company’s stock in a transaction on Thursday, August 25th. The shares were bought at an average price of $6.82 per share, with a total value of $25,302.20. Following the transaction, the chief financial officer now owns 3,710 shares in the company, valued at $25,302.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.85% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the company. ProShare Advisors LLC increased its stake in Neos Therapeutics by 10.0% in the second quarter. ProShare Advisors LLC now owns 13,622 shares of the company’s stock valued at $126,000 after buying an additional 1,233 shares in the last quarter. Schwab Charles Investment Management Inc. bought a new stake in Neos Therapeutics during the second quarter valued at $200,000. Teachers Advisors Inc. increased its stake in Neos Therapeutics by 289.6% in the second quarter. Teachers Advisors Inc. now owns 21,924 shares of the company’s stock valued at $203,000 after buying an additional 16,296 shares in the last quarter. California State Teachers Retirement System increased its stake in Neos Therapeutics by 140.1% in the second quarter. California State Teachers Retirement System now owns 28,815 shares of the company’s stock valued at $267,000 after buying an additional 16,815 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Neos Therapeutics by 73.1% in the second quarter. Bank of New York Mellon Corp now owns 38,008 shares of the company’s stock valued at $353,000 after buying an additional 16,046 shares in the last quarter. 37.73% of the stock is currently owned by institutional investors.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.